PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease ReportsObstructive sleep apnea
MeSH D020181 - obstructive sleep apnea
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D012891:Sleep apnea syndromes
0 Companies
0 Drugs
Success rate
D020181: 
Obstructive sleep apnea
12 Companies
6 Drugs
$
Success rate
D010845:Obesity hypoventilation syndrome
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Alembic PharmaceuticalsModafinil Modafinil  2012-10-18   
AllerganModafinil Modafinil  2012-11-01   
ApotexModafinil Modafinil  2014-02-03   
Appco PharmaModafinil Modafinil  2017-08-16   
Atnahs PharmaceuticalsSolriamfetol Sunosi  2020-01-16   
Aurobindo PharmaModafinil Modafinil  2012-09-27   
BioprojetPitolisant Ozawade  2021-09-01   
GSKUmeclidinium, Fluticasone furoate, Vilanterol Elebrato Ellipta  2017-11-15   
Fluticasone furoate, Vilanterol Relvar Ellipta  2013-11-13   
Fluticasone furoate, Vilanterol Revinty Ellipta  2014-05-02   
Umeclidinium, Fluticasone furoate, Vilanterol Temybric Ellipta  2019-06-12   
Umeclidinium, Fluticasone furoate, Vilanterol Trelegy Ellipta  2017-11-15   
Hikma PharmaceuticalsModafinil Modafinil  2012-09-26   
NATCO PharmaModafinil Modafinil  2012-07-16   
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
63%
17/27
Phase 2
38%
15/40
Phase 3
59%
20/34
Approved: 3Overall Success rate: 14%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
GSK
Fluticasone furoate,
Umeclidinium,
Umeclidinium bromide,
Vilanterol,
Vilanterol acetate
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use